34 related articles for article (PubMed ID: 28927158)
1. De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance.
Nie ZY; Yao M; Yang Z; Yang L; Liu XJ; Yu J; Ma Y; Zhang N; Zhang XY; Liu MH; Jiang LL; Luo JM
J Exp Clin Cancer Res; 2020 Jan; 39(1):17. PubMed ID: 31952546
[TBL] [Abstract][Full Text] [Related]
2. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
3. Activation of HtrA2, a mitochondrial serine protease mediates apoptosis: current knowledge on HtrA2 mediated myocardial ischemia/reperfusion injury.
Bhuiyan MS; Fukunaga K
Cardiovasc Ther; 2008; 26(3):224-32. PubMed ID: 18786092
[TBL] [Abstract][Full Text] [Related]
4. Regulation of HtrA2 on WT1 gene expression under imatinib stimulation and its effects on the cell biology of K562 cells.
Zhang L; Li Y; Li X; Zhang Q; Qiu S; Zhang Q; Wang M; Xing H; Rao Q; Tian Z; Tang K; Wang J; Mi Y
Oncol Lett; 2017 Sep; 14(3):3862-3868. PubMed ID: 28927158
[TBL] [Abstract][Full Text] [Related]
5. Omi/HtrA2 Regulates a Mitochondria-Dependent Apoptotic Pathway in a Murine Model of Septic Encephalopathy.
Wang P; Hu Y; Yao D; Li Y
Cell Physiol Biochem; 2018; 49(6):2163-2173. PubMed ID: 30286467
[TBL] [Abstract][Full Text] [Related]
6. [Increasing sensitivity of leukemia cells to imatinib by inhibiting NHE1 and p38MAPK signaling pathway].
Hu RH; Jin WN; Chang GQ; Lin YN; Wang J; Ru YX; Li QH; Pang TX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1341-5. PubMed ID: 23257429
[TBL] [Abstract][Full Text] [Related]
7. Omi/HtrA2 Protease Associated Cell Apoptosis Participates in Blood-Brain Barrier Dysfunction.
Hu Y; Bi Y; Yao D; Wang P; Li Y
Front Mol Neurosci; 2019; 12():48. PubMed ID: 30853894
[No Abstract] [Full Text] [Related]
8. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
9. Ucf-101 protects in vivoandin vitro models of PD against 6-hydroxydopamine toxicity by alleviating endoplasmic reticulum stress via the Wnt/β-catenin pathway.
Li Y; Liu Z; Wang D; Gao H; Zhu Z; Wang Y; Luo Q; Jiang S; Zhang J; Yang X
J Clin Neurosci; 2020 Jan; 71():217-225. PubMed ID: 31883812
[TBL] [Abstract][Full Text] [Related]
10. Role of the Wilms' tumor 1 gene in the aberrant biological behavior of leukemic cells and the related mechanisms.
Li Y; Wang J; Li X; Jia Y; Huai L; He K; Yu P; Wang M; Xing H; Rao Q; Tian Z; Tang K; Wang J; Mi Y
Oncol Rep; 2014 Dec; 32(6):2680-6. PubMed ID: 25310451
[TBL] [Abstract][Full Text] [Related]
11. Exogenous expression of WT1 gene influences U937 cell biological behaviors and activates MAPK and JAK-STAT signaling pathways.
Li X; Li Y; Yuan T; Zhang Q; Jia Y; Li Q; Huai L; Yu P; Tian Z; Tang K; Wang M; Xing H; Rao Q; Mi Y
Leuk Res; 2014 Aug; 38(8):931-9. PubMed ID: 24894814
[TBL] [Abstract][Full Text] [Related]
12. Role of hTERT and WT1 gene expression in disease progression and imatinib responsiveness of patients with BCR-ABL positive chronic myeloid leukemia.
Varma N; Anand MS; Varma S; Juneja SS
Leuk Lymphoma; 2011 Apr; 52(4):687-93. PubMed ID: 21314483
[TBL] [Abstract][Full Text] [Related]
13. HtrA2, taming the oncogenic activities of WT1.
Hartkamp J; Roberts SG
Cell Cycle; 2010 Jul; 9(13):2508-14. PubMed ID: 20543571
[TBL] [Abstract][Full Text] [Related]
14. The Wilms' tumor suppressor protein WT1 is processed by the serine protease HtrA2/Omi.
Hartkamp J; Carpenter B; Roberts SG
Mol Cell; 2010 Jan; 37(2):159-71. PubMed ID: 20122399
[TBL] [Abstract][Full Text] [Related]
15. WT1 expression in peripheral leukocytes of patients with chronic myeloid leukemia serves for the prediction of Imatinib resistance.
Otahalova E; Ullmannova-Benson V; Klamova H; Haskovec C
Neoplasma; 2009; 56(5):393-7. PubMed ID: 19580340
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
